Corporate reports and policies

Annual reports

The document includes the Report of the Board of Trustees, an Independent Auditors’ report, and our statement of financial activities, balance sheet, cash flow and notes to the accounts.

Our policy priorities

We believe there are three areas the Government could prioritise to enable cancer research in academic institutions to thrive, and help us on our mission to continue making the discoveries that defeat cancer.
Patient and doctor sat next to one another reviewing treatment document

Improving access to clinical trials

Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Tablets of abiraterone acetate, a drug discovered and developed at the ICR

Improving drug access

It is essential that we can harness advances in science to bring innovative drugs to people with cancer.
Biomarkers immunofluorescence

Use of biomarkers in cancer research and treatment

Biomarkers – biological tests that give key information about a patient – have a huge role to play in the future of precision medicine which is why ten leading institutions, charities, stakeholder groups and life-science companies have developed a new set of 13 consensus statements aiming to drive wider use of biomarkers and more effective use of precision medicine for cancer patients.
Sir Richard Doll Building in Sutton

Annual Report on Bullying and Harassment

The ICR has a zero tolerance policy towards bullying and harassment in the workplace.